58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

Differential Diagnosis of Chronic Nausea & Vomiting

Nausea and vomiting are common, non-specific gastrointestinal symptoms. When symptoms persist for longer than 4 weeks, they are designated as chronic, necessitating a structured diagnostic evaluation. The initial clinical imperative is distinguishing neuromuscular motility disorders and mechanical obstructions from functional gastrointestinal disorders and substance-induced hyperemesis syndromes.

                  DIFFERENTIAL DIAGNOSIS OF CHRONIC NAUSEA AND EMETIC SYNDROMES

   Clinical Entity         Key Pathophysiology & Triggers          Distinctive Clinical Features & Hallmarks
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Gastroparesis           Neuromuscular gastric motor failure     Postprandial fullness, early satiety, vomiting of
                           (vagal neuropathy, loss of nNOS, loss   undigested food eaten hours earlier; succession splash;
                           of Interstitial Cells of Cajal [ICC])   erratic glycemic control in diabetics. Normal EGD;
                                                                   objective delay on 4-hour scintigraphy (> 10% retention).
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Functional Dyspepsia    Rome IV criteria: Visceral hypersensitivity, Bothersome postprandial fullness or early satiation
   (Postprandial Distress  impaired gastric fundic accommodation,  preventing meal completion >= 3 days/week. Upper
   Syndrome [PDS])         or altered brain-gut axis processing    endoscopy is completely normal; gastric emptying is normal.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Functional Dyspepsia    Rome IV criteria: Central processing of Epigastric pain or burning >= 1 day/week, not strictly
   (Epigastric Pain        gastric sensory input; abnormal mucosal postprandial, not relieved by defecation. Normal EGD.
   Syndrome [EPS])         permeability and low-grade inflammation  First-line therapy: PPIs; second-line: TCAs (nortriptyline).
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Cannabinoid Hyperemesis Chronic, heavy, daily/near-daily        Cyclic paroxysms of severe intractable nausea, vomiting,
   Syndrome (CHS)          cannabis use (> 1-2 years). Gut CB1     and colicky abdominal pain. Pathognomonic learned behavior:
                           downregulation + hypothalamic           COMPULSIVE SCALDING HOT SHOWERS/BATHS providing prompt
                           thermoregulatory/emetic dysregulation   temporary relief. Completely cured by CANNABIS CESSATION.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Cyclic Vomiting         Mitochondrial DNA mutations; central    Stereotypical acute emetic episodes lasting hours to days,
   Syndrome (CVS)          autonomic dysregulation. Personal or    separated by completely asymptomatic intervals of weeks
                           family history of MIGRAINE HEADACHES    to months. Responsive to triptans and tricyclic prophylaxis.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Gastric Outlet          Physical lumen-occluding lesion:        Progressive postprandial vomiting of undigested food,
   Obstruction (GOO)       peptic ulcer stricture, gastric adenocarcinoma, profound weight loss, succession splash. Upper endoscopy
                           pancreatic cancer, duodenal stenosis    is diagnostic, revealing mechanical lumen occlusion.
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

Cannabinoid Hyperemesis Syndrome (CHS)

With the expanding legalization and potency of tetrahydrocannabinol (THC) products, Cannabinoid Hyperemesis Syndrome has emerged as a major cause of recurring emergency department visits:

• Pathophysiology: While cannabis possesses well-known antiemetic properties at low doses, chronic high-dose exposure overstimulates and downregulates enteric cannabinoid-1 (CB1) receptors in the myenteric plexus, impairing gastric motility. Concurrently, lipophilic cannabinoids accumulate in cerebral adipose stores, triggering paradoxical dysregulation of hypothalamic thermoregulatory and emetic control centers.
• The Hot Water Bathing Phenomenon: Patients discover that submerged exposure to scalding hot water provides rapid, dramatic, but temporary relief of nausea. Heat application activates cutaneous transient receptor potential vanilloid-1 (TRPV1) receptors, increasing splanchnic blood flow and overriding aberrant hypothalamic thermoregulatory circuits.
• Management: Conventional antiemetics (ondansetron, promethazine, metoclopramide) are characteristically ineffective. Acute distress is relieved by topical capsaicin 0.025% cream applied to the periumbilical region (activating cutaneous TRPV1 receptors) or intravenous haloperidol/droperidol. The only definitive and curative intervention is complete, permanent cessation of all cannabis consumption; emetic episodes resolve completely within 1 to 3 months of abstinence.

---

Diabetic & Idiopathic Gastroparesis: Pathophysiology & Features

Gastroparesis is defined as a chronic neuromuscular disorder characterized by objectively delayed gastric emptying of solid food in the absence of mechanical gastric outlet obstruction.

Etiological Breakdown

• Diabetic Gastroparesis (~30% to 35%): The most prevalent identifiable etiology. It develops in patients with longstanding (typically >10 years), poorly controlled type 1 or type 2 diabetes mellitus (T1D > T2D), and is almost universally accompanied by other manifestations of microvascular disease, including diabetic retinopathy, peripheral sensory neuropathy, and diabetic nephropathy.
• Idiopathic Gastroparesis (~50%): Represents the largest single cohort, occurring predominantly in young to middle-aged females (female-to-male ratio ~4:1). A distinct subset represents post-viral gastroparesis following acute gastroenteritis or systemic infection (e.g., cytomegalovirus [CMV], Epstein-Barr virus [EBV], norovirus, rotavirus). Post-viral gastroparesis carries a favorable natural history, with gradual symptomatic and physiological recovery over 1 to 3 years.
• Post-Surgical Gastroparesis (~10% to 15%): Results from accidental iatrogenic injury to or complete transection of the vagus nerve (truncal vagotomy) during Nissen fundoplication, bariatric surgery (sleeve gastrectomy, Roux-en-Y gastric bypass), esophagectomy, or peptic ulcer operations.
• Medication-Induced Delayed Emptying: Must be excluded before confirming primary gastroparesis. Prominent offending pharmacotherapies include GLP-1 receptor agonists and dual GIP/GLP-1 RAs (semaglutide, tirzepatide), amylin analogs (pramlintide), opioid analgesics (morphine, oxycodone, fentanyl), anticholinergics / antispasmodics (dicyclomine, hyoscyamine, scopolamine), and tricyclic antidepressants.

Neuropathology: The Cellular Triad

The neuromuscular deficit in gastroparesis involves three interrelated pathological mechanisms:

1. Autonomic Vagal Neuropathy: Axonal swelling, demyelination, and degeneration of unmyelinated preganglionic vagal efferent fibers, disrupting parasympathetic motor stimulation to the gastric muscularis.
2. Loss of Neuronal Nitric Oxide Synthase (nNOS): Inhibitory motor neurons within the myenteric plexus fail to synthesize nitric oxide (NO). Nitric oxide is required for normal postprandial gastric fundic accommodation (the receptive relaxation of the proximal stomach that accommodates ingested food volume without increasing intragastric pressure). Loss of nNOS prevents accommodation, yielding rapid intragastric pressure spikes that trigger early satiety and nausea.
3. Depletion of Interstitial Cells of Cajal (ICC): The Interstitial Cells of Cajal are specialized mesenchymal pacemaker cells embedded within the circular muscular layer that generate the spontaneous gastric electrical slow waves at a physiological frequency of 3 cycles per minute (cpm). In gastroparesis, extensive loss or phenotypic dedifferentiation of ICC uncouples electromechanical signaling, producing gastric dysrhythmias (tachygastria >3.7 cpm or bradygastria <2.5 cpm), profound antral hypomotility, and functional pylorospasm (failure of the pyloric sphincter to coordinate relaxation with antral contractions).

Clinical Presentation

• Early Satiety: Inability to consume a normal-sized meal; feeling uncomfortably full after only a few bites of food.
• Postprandial Fullness & Epigastric Bloating: Protracted, uncomfortable sensation of food stagnating in the upper abdomen.
• Vomiting of Undigested Food: Vomiting characteristically occurs several hours after meal ingestion and contains identifiable food fragments consumed 6, 12, or even 24 hours earlier, without bile staining.
• Physical Examination Hallmark: The Gastric Succession Splash: Performed by placing the stethoscope over the epigastrium and rocking the patient's pelvis or upper abdomen from side to side. The detection of a sloshing or splashing sound >3 to 4 hours after a meal indicates retained fluid and gas in a dilated, non-emptying stomach, providing strong physical evidence of gastric stasis or mechanical obstruction.

                  THE DIABETIC GASTROPARESIS GLYCEMIC ROLLERCOASTER

   Phase                   Physiological Event                         Glycemic Consequence
   ═════════════════════════════════════════════════════════════════════════════════════════════════
   Early Postprandial      Preprandial bolus insulin is administered    UNEXPECTED HYPOGLYCEMIA
   (0 to 2 hours)          and reaches peak pharmacodynamic action,     (Insulin acts on circulation while
                           but food remains sequestered in stomach      carbohydrates are trapped in stomach)
   ─────────────────────────────────────────────────────────────────────────────────────────────
   Late Postprandial       Hours later, the retained gastric chyme      UNEXPECTED SEVERE HYPERGLYCEMIA
   (4 to 8 hours)          finally empties unpredictably into the       (Sudden carbohydrate absorption
                           duodenum; prandial insulin has dissipated     after bolus insulin has cleared)
   ═════════════════════════════════════════════════════════════════════════════════════════════════

---

Diagnostic Workup: Endoscopy & Gastric Emptying Scintigraphy

The diagnostic algorithm for suspected gastroparesis requires a mandatory two-step sequence: 1) exclude physical mechanical obstruction via endoscopy, and 2) quantify delayed gastric transit using standardized solid-phase scintigraphy.

Step 1: Mandatory Upper Endoscopy (EGD)

• Exclusion of Mechanical Obstruction: Upper endoscopy is mandatory to rule out mechanical gastric outlet obstruction (peptic strictures, pyloric stenosis, infiltrating gastric adenocarcinoma, extrinsic pancreatic neoplasia compressing the duodenum, or large hiatal hernia with organoaxial volvulus).
• Key Endoscopic Sign of Gastroparesis: The identification of retained solid food in the stomach after an overnight fast (>=12 hours) in the absence of mechanical obstruction or recent general anesthesia is highly pathognomonic for gastroparesis.
• Gastric Phytobezoar Detection: Gastric stasis permits the coalescence of undigested vegetable matter (cellulose, hemicellulose, lignin from celery, oranges, persimmons, seeds) into dense, obstructing foreign bodies designated as phytobezoars, which cause mechanical irritation, mucosal ulceration, and bleeding.

Step 2: Diagnostic Gold Standard: 4-Hour Gastric Emptying Scintigraphy (GES)

Once mechanical obstruction is excluded, the patient must undergo a standardized 4-hour solid-phase Gastric Emptying Scintigraphy (GES) study, performed according to consensus protocols established by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Neurogastroenterology and Motility Society (ANMS):

                  STANDARDIZED 4-HOUR SOLID-PHASE GASTRIC EMPTYING PROTOCOL

   Component               Standardized Consensus Requirements & Criteria
   ═════════════════════════════════════════════════════════════════════════════════════════════════════
   Standard Test Meal      • 4 oz (118 mL) liquid egg whites (or equivalent egg substitute)
                             radiolabeled with 0.5 to 1.0 mCi Technetium-99m (99mTc) sulfur colloid
                           • 2 slices of toasted white bread
                           • 30 grams of strawberry jam
                           • 120 mL of water
                           (Total nutritional profile: ~255 kcal, 2% fat, 72% carbohydrate, 24% protein)
   ─────────────────────────────────────────────────────────────────────────────────────────────────
   Image Acquisition       Planar anterior and posterior gamma camera images obtained immediately post-meal
                           (time 0), and at 1 hour, 2 hours, and 4 hours.
   ─────────────────────────────────────────────────────────────────────────────────────────────────
   Diagnostic Thresholds   • NORMAL: <= 10% gastric retention at 4 hours
   for Delayed Emptying    • DIAGNOSTIC FOR GASTROPARESIS: > 10% gastric retention at 4 hours
                             (Alternatively: > 60% gastric retention at 2 hours)
   ─────────────────────────────────────────────────────────────────────────────────────────────────
   Severity Stratification • Grade 1 (Mild):     11% to 15% retention at 4 hours
                           • Grade 2 (Moderate): 16% to 35% retention at 4 hours
                           • Grade 3 (Severe):   36% to 50% retention at 4 hours
                           • Grade 4 (Very Severe): > 50% retention at 4 hours
   ═════════════════════════════════════════════════════════════════════════════════════════════════

[!IMPORTANT] THE 4-HOUR RULE & MANDATORY PRE-TEST PRECAUTIONS

1. THE 4-HOUR REQUIREMENT: Imaging at 1 or 2 hours alone is grossly inadequate. Up to 30% of patients with documented gastroparesis exhibit normal or equivocal emptying at 2 hours but demonstrate abnormal retention at 4 hours. The 4-hour measurement is the single most sensitive and specific diagnostic cutoff.
2. MEDICATION WITHHOLDING PROTOCOL: All medications that accelerate or delay gastrointestinal motility MUST BE WITHHELD FOR AT LEAST 48 TO 72 HOURS PRIOR TO TESTING:
   • Withhold Opioids (morphine, oxycodone, tramadol) and Anticholinergics (dicyclomine, hyoscyamine, scopolamine) — prevent false-positive delays.
   • Withhold GLP-1 Receptor Agonists and dual GIP/GLP-1 RAs (semaglutide, tirzepatide) — prevent drug-induced delays.
   • Withhold Prokinetics (metoclopramide, erythromycin, domperidone) — prevent false-negative normalizations.
3. THE GLYCEMIC CUTOFF (< 275 mg/dL): On the morning of and throughout the 4-hour examination, the patient's blood glucose MUST BE MAINTAINED < 275 mg/dL (< 15.3 mmol/L). Acute hyperglycemia directly impairs vagal efferent motor output and delays gastric emptying even in healthy individuals. Testing an acutely hyperglycemic patient yields a false-positive result reflecting acute metabolic inhibition rather than chronic neuromuscular gastroparesis.

Comprehensive Management of Gastroparesis

The therapeutic approach combines dietary restructuring, glycemic optimization, prokinetic pharmacotherapy, antiemetic agents, and advanced interventional techniques.

1. Dietary & Lifestyle Modifications

Dietary modification represents the foundational first-line therapy across all disease stages:

• Small, Frequent Feedings: Instruct patients to consume 4 to 6 small meals daily rather than 2 to 3 large meals. This reduces intragastric volume, prevents acute fundic distension, and facilitates residual antral grinding.
• Low-Fat Nutritional Prescription: High-fat meals stimulate duodenal CCK release, which triggers inhibitory feedback loops that halt gastric contractions. Fat intake should be restricted to low-fat or fat-free alternatives.
• Low-Insoluble-Fiber Diet: Insoluble plant fibers (raw vegetables, citrus pulp, peels, seeds, legumes, nuts, celery, broccoli) resist enzymatic breakdown and depend entirely on vigorous mechanical antral milling. In an atonic stomach, undigested insoluble fibers aggregate to form obstructing gastric phytobezoars. Patients must avoid raw fibrous produce, consuming only well-cooked, pureed, or canned fruits and vegetables without skins.
• Blended, Pureed & Liquid Calories: Liquid phase gastric emptying depends primarily on the gastroduodenal hydrostatic pressure gradient and gravity, remaining largely preserved even in severe antral neuromuscular failure. Patients struggling with weight loss should shift caloric intake toward high-protein smoothies, nutrient-dense broths, pureed soups, and commercial liquid nutritional formulations.
• Postprandial Posture: Patients must remain seated upright or engage in gentle ambulation for at least 2 hours following meals; recumbency immediately postprandially must be strictly avoided.

2. Glycemic Optimization in Diabetics

• In patients with diabetes mellitus, continuous glucose monitoring (CGM) is vital for detecting asymptomatic hypoglycemia and delayed postprandial spikes.
• Insulin Administration Timing: To prevent the classic mismatch between insulin action and delayed food absorption, mealtime rapid-acting insulin should NOT be administered before meals. Instead, instruct the patient to administer rapid-acting insulin immediately AFTER the meal (or split the dose: 50% immediately post-meal, and 50% 60 to 90 minutes later based on actual food retention).
• Discontinue GLP-1 receptor agonists and pramlintide, as both classes potently suppress gastric motility.

3. Prokinetic Pharmacotherapy

                  PROKINETIC PHARMACOTHERAPY COMPARISON IN GASTROPARESIS

   Agent                 Mechanism of Action             Dosing & Regimen                Key Regulatory Nuances & Adverse Effects
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Metoclopramide        Dopamine D2 receptor            5 to 10 mg PO TID or QID        • ONLY FDA-APPROVED DRUG FOR GASTROPARESIS.
   (Reglan)              antagonist + 5-HT4 agonist      (30 min before meals & bedtime) • BLACK BOX WARNING: TARDIVE DYSKINESIA!
                         (Central antiemetic + enteric   Reduce dose 50% in renal        • LIMIT TREATMENT TO <= 12 WEEKS.
                         prokinetic motor stimulator)    impairment (eGFR < 40 mL/min)   • Acute dystonia, akathisia, hyperprolactinemia.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
   Erythromycin          Motilin receptor agonist        125 to 250 mg PO TID            • Powerful acute prokinetic motor stimulant.
   (Oral or IV)          (Induces migrating motor        (30 min before meals);          • RAPID TACHYPHYLAXIS occurs within 2 to 4 weeks
                         complexes in stomach/duodenum)  IV 3 mg/kg q8h for acute flares   due to motilin receptor downregulation.
                                                                                         • Use as short-term bridge; QTc prolongation.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
   Domperidone           Peripheral Dopamine D2          10 mg PO TID to QID             • Does NOT cross the blood-brain barrier!
   (Motilium)            receptor antagonist             (30 min before meals & bedtime) • NO EXTRA PYRAMIDAL SYMPTOMS OR TARDIVE DYSKINESIA.
                         (Prokinetic + antiemetic)                                       • Available ONLY via FDA EXPANDED ACCESS IND.
                                                                                         • Risk of QTc prolongation; requires baseline ECG.
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════

Metoclopramide & The Tardive Dyskinesia Black Box Warning

• Mechanism: Metoclopramide is a substituted benzamide that stimulates upper gastrointestinal motility by antagonizing inhibitory enteric dopamine D2 receptors and agonizing 5-HT4 receptors (stimulating presynaptic acetylcholine release). It concurrently blocks dopamine D2 receptors in the area postrema / chemoreceptor trigger zone, providing potent central antiemetic activity.
• Black Box Warning: Metoclopramide readily crosses the blood-brain barrier, blocking central striatal dopamine receptors. This carries a high risk of drug-induced extrapyramidal symptoms and potentially irreversible Tardive Dyskinesia (TD):
  • Clinical Manifestations of TD: Involuntary, repetitive, choreoathetoid movements of the tongue, face, lips, and facial musculature (e.g., lip smacking, puckering, grimacing, tongue protrusion, chewing movements, rapid blinking) and choreiform movements of the extremities and trunk.
  • Risk Factors: Advanced age (especially elderly females), diabetes mellitus, cumulative drug dosage, and prolonged duration of therapy.
  • MANDATORY PRESCRIBING RESTRICTION: The FDA explicitly mandates that continuous treatment with metoclopramide MUST NOT EXCEED 12 WEEKS.
  • Clinical Action: If involuntary facial or motor movements appear, metoclopramide must be discontinued immediately; however, tardive dyskinesia frequently persists indefinitely despite cessation.
  • Acute Dystonic Reactions: Occur early in therapy (oculogyric crisis, trismus, torticollis); managed acutely with parenteral diphenhydramine (25 to 50 mg IV/IM) or benztropine (1 to 2 mg IV/IM).

Erythromycin & The Tachyphylaxis Trap

• Mechanism: Erythromycin mimics native motilin by binding motilin receptors on gastrointestinal smooth muscle, triggering forceful Phase III migrating motor complexes.
• Tachyphylaxis: The motilin receptor undergoes rapid phosphorylation, internalization, and downregulation within 2 to 4 weeks of continuous therapy, causing near-total loss of prokinetic efficacy. Consequently, oral erythromycin cannot be used for long-term chronic maintenance; its clinical utility is restricted to short-term bridging (1 to 3 weeks) during acute inpatient exacerbations or pulsed, intermittent schedules.

Domperidone

• Domperidone is a potent peripheral dopamine D2 receptor antagonist. Because of its high molecular weight and low lipophilicity, it does not cross the blood-brain barrier.
• It provides prokinetic and antiemetic efficacy equivalent to metoclopramide WITHOUT the risk of central extrapyramidal symptoms or tardive dyskinesia.
• Because it can prolong the cardiac QTc interval and cause fatal ventricular arrhythmias, it is not approved for general commercial sale in the United States; physicians must obtain it through the FDA Expanded Access Investigational New Drug (IND) program, with mandatory baseline and follow-up 12-lead electrocardiography (discontinue if QTc exceeds 470 ms in males or 480 ms in females).

4. Symptomatic Antiemetic Therapies

• Serotonin 5-HT3 Receptor Antagonists: Ondansetron (4 to 8 mg PO/ODT TID prn) or granisetron. Highly effective for acute nausea; does not accelerate gastric emptying, but provides central and peripheral antiemetic control. Common adverse effects include headache, constipation, and mild QTc prolongation.
• Phenothiazines & Antihistamines: Promethazine (12.5 to 25 mg PO/PR q4-6h prn) or prochlorperazine. Provides antiemetic relief; however, sedating effects and central anticholinergic activity can theoretically worsen gastric stasis.

5. Advanced & Refractory Interventions

For patients with intractable, debilitating gastroparesis refractory to aggressive dietary modifications and prokinetic pharmacotherapy:

• Gastric Electrical Stimulation (Enterra Device):
  • A surgically implanted neurostimulator placed in a subcutaneous abdominal pocket, with two bipolar intramuscular leads anchored into the muscularis propria of the gastric greater curvature.
  • Delivers high-frequency (12 cpm), low-energy electrical pulses.
  • Approved by the FDA under a Humanitarian Device Exemption (HDE) for severe diabetic or idiopathic gastroparesis.
  • Clinical Mechanism: Does not significantly accelerate gastric emptying rates; instead, it stimulates afferent vagal pathways projecting to the brainstem solitary tract nucleus, substantially reducing nausea, vomiting frequency, and healthcare utilization.
• Gastric Per-Oral Endoscopic Myotomy (G-POEM):
  • A minimally invasive endoscopic procedure utilizing submucosal tunneling to perform a selective circular pyloromyotomy (endoscopic division of the hypertrophied pyloric sphincter).
  • Drastically reduces pyloric outflow resistance, accelerating gastric emptying and resolving symptoms in patients with documented pylorospasm.
• Enteral Nutrition via Jejunostomy (J-Tube):
  • Indicated for severe, refractory gastroparesis complicated by progressive weight loss (>10% body weight), severe malnutrition, or recurrent hospitalizations for dehydration.
  • A surgical or endoscopically placed jejunostomy tube (J-tube) delivers continuous enteral nutrition directly into the functional small bowel, completely bypassing the paralyzed stomach.
  • Clinical Pearl: Standard Gastrostomy tubes (G-tubes) MUST NEVER be used for enteral feeding in gastroparesis, as infused feeding will stagnate, provoke severe vomiting, and induce pulmonary aspiration. G-tubes are reserved strictly for passive decompression and venting of retained gas and secretions.